| ★ |  EPL Improves Steatosis, Fatigue in Patients With MASLD, WIth Zobair Younossi, MD | | 63 | Estados Unidos | |
| 17 |  Reversing Fatigue Aging and Chronic Disease Through Mitochondrial Support | Medical Centric Podcast @medicalcentric | — | Portugal | 84 |
| 8 |  Fatty Liver Fixed by Ozempic (GLP-1) | Dr Brad Stanfield @drbradstanfield | 7.4K | Nueva Zelanda | 85 |
| 4 |  The Hidden Metabolic Cause of Fatty Liver Disease | Metabolic Mind @metabolicmind | 6.1K | Estados Unidos | 86 |
| 13 |  La vérité sur le ghee | Naturacademy / Benjamin Dariouch @naturacademy_ | 2.1K | Francia | 84 |
| 7 |  NCDs, obesity and liver health – Can the EU turn the tide? | | 1.6K | Bélgica | 85 |
| 12 |  Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D | | 1.6K | Estados Unidos | 84 |
| 16 |  Lean NAFLD: Fatty Liver Disease in Non Obese Adults Explained | Medical Centric Podcast @medicalcentric | 1.3K | Portugal | 84 |
| 19 |  The Surprising Cure for Fatty Liver Disease | Dr. Neil Nedley | Nedley Health @nedleyhealth | 1.3K | Estados Unidos | 83 |
| 11 |  1 in 4 People Have Fatty Liver: Here’s How To Reverse It Naturally | | 1.1K | Estados Unidos | 84 |
| 2 |  Triglyceride-Glucose Index Associated With Risk of End-Stage Liver Disease in MASLD | | 639 | Estados Unidos | 87 |
| 14 |  Salud Hepática como Clave de la Homeostasis Sistémica: Estrategias Clínicas con una nueva fórmula | Basic Farm @basicfarmoficial | 111 | Colombia | 84 |
| 6 |  MAESTRO-NASH: Resmetirom May Reduce Cardiovascular Risk in MASH, With or Without Statins | | 86 | Estados Unidos | 85 |
| 20 |  Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care | | 59 | Estados Unidos | 83 |
| 3 |  METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy | | 57 | Estados Unidos | 86 |
| 9 |  Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy | | 55 | Estados Unidos | 84 |
| 1 |  Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework | | 48 | Estados Unidos | 89 |
| 15 |  IMPACTO DE LOS ANTIDIABÉTICOS EN LAPROGRESIÓN DE MASLD. | | 46 | — | 84 |
| 5 |  Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy | | 40 | Estados Unidos | 86 |
| 18 |  Closing Chronic Liver Disease Gaps Requires Earlier Detection, Community Outreach | | 17 | Estados Unidos | 83 |
| 10 |  Medical breakthrough reveals the hidden cause of liver disease | | 14 | Estados Unidos | 84 |